BriaCell Therapeutics Corp.
Nasdaq · CIK 0001610820 · Fiscal year end 0731
Latest reported period: Latest published period
Operating Income
$-23.5M
Net Income
$-22.6M
Eps Basic
-5.73
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-23.5M | - | - |
| Net Income | $-22.6M | - | - |
| Eps Basic | -5.73 | - | - |
| Eps Diluted | -5.73 | - | - |
| Cash And Equivalents | $6.9M | - | - |
| Total Assets | $27.1M | - | - |
| Operating Cash Flow | $-22.7M | - | - |
| Capital Expenditures | $127,049 | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | BriaCell Therapeutics Corp. | 2026-06-09 | 0001493152-26-027928 |
| 10-Q | BriaCell Therapeutics Corp. | 2026-03-10 | 0001493152-26-009557 |
| 10-Q | BriaCell Therapeutics Corp. | 2025-12-11 | 0001493152-25-027240 |
| 10-K | BriaCell Therapeutics Corp. | 2025-10-16 | 0001493152-25-018212 |